Cynthia Butitta, the former chief operating officer of Kite Pharma (now Gilead Sciences Inc), has joined Autolus Ltd as a member of its board of directors. Autolus is developing T cell therapies for cancer. At Kite, Ms Butitta she helped secure more than $1 billion in equity financing. The company was sold to Gilead for $11.9 billion in 2017. Ms Butitta received a BS degree in business and accounting from Edgewood College in Wisconsin, US and an MBA in finance from the University of Wisconsin.
Autolus announced the appointment on 12 March 2018.
Copyright 2018 Evernow Publishing Ltd.